CAS: 958852-01-2 - GSK1059615
Fórmula:C18H11N3O2S
- Sinónimos:
- Gsk 1059615
- 5-[[4-(4-Pyridinyl)-6-quinolinyl]methylene]-2,4-thiazolidenedione
- (5Z)-5-[[4-(4-Pyridinyl)-6-quinolinyl]methylene]-2,4-thiazolidinedione
- (Z)-5-((4-(pyridin-4-yl)quinolin-6-yl)methylene)thiazolidine-2,4-dione
| Marca | Datos del producto | Pureza | Rango de precios | Entrega estimada |
|---|---|---|---|---|
 | GSK1059615 REF: IN-DA005WY2CAS: 958852-01-2 | 98% | 90,00 €~600,00 € | Lun 18 Nov 24 |
 | GSK1059615 REF: TM-T2357CAS: 958852-01-2 | ≥95% - ≥95% | 43,00 €~420,00 € | Lun 25 Nov 24 |
 | GSK 1059615 REF: TR-G797803CAS: 958852-01-2 | - - - | 3.578,00 € | Jue 02 Ene 25 |
 | (Z)-5-((4-(pyridin-4-yl)quinolin-6-yl)methylene)thiazolidine-2,4-dione REF: 3D-FP43332CAS: 958852-01-2 | Min. 95% | A consultar | Lun 30 Dic 24 |
Ref: IN-DA005WY2
| 5mg | 90,00 € | ||
| 10mg | 111,00 € | ||
| 25mg | 156,00 € | ||
| 50mg | 262,00 € |
Entrega estimada en Estados Unidos, el Lunes 18 de Noviembre de 2024
GSK1059615
CAS:958852-01-2
GSK1059615 has been used in trials studying the treatment of Lymphoma, Solid Tumours, Endometrial Cancer, …
Fórmula:
C18H11N3O2S
Pureza:
≥95% - ≥95%
Forma y color:
Solid
Peso molecular:
333.36
Ref: TM-T2357
| 5mg | 43,00 € | ||
| 10mg | 62,00 € | ||
| 25mg | 116,00 € | ||
| 50mg | 203,00 € | ||
| 100mg | 292,00 € | ||
| 200mg | 420,00 € |
Entrega estimada en Estados Unidos, el Lunes 25 de Noviembre de 2024
GSK 1059615
Producto controladoCAS:958852-01-2
Fórmula:
C18H11N3O2S
Forma y color:
Neat
Peso molecular:
333.364
Ref: TR-G797803
| 250mg | 3.578,00 € |
Entrega estimada en Estados Unidos, el Jueves 2 de Enero de 2025
(Z)-5-((4-(pyridin-4-yl)quinolin-6-yl)methylene)thiazolidine-2,4-dione
CAS:958852-01-2
(Z)-5-((4-(Pyridin-4-yl)quinolin-6-yl)methylene)thiazolidine-2,4-dione is a potent inhibitor of the epidermal growth factor receptor (EGFR). It has been …
Pureza:
Min. 95%
Ref: 3D-FP43332
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar |
Entrega estimada en Estados Unidos, el Lunes 30 de Diciembre de 2024
